Gilead intends to produce 2 million courses of ramdevpir therapy COVID-19

Gilead announced the intention to release more than 2 million courses of the drug ramdevpir, which is regarded as an effective means of therapy for coronavirus infection. The company also plans to conduct clinical studies with inhaled forms of the drug, writes Reuters.

Antiretroviral ramdevpir was the first drug that demonstrated in clinical studies its effectiveness in the treatment of coronavirus infection. In some countries (including the US) have allowed its use in the fight against the pandemic COVID-19.

Currently, medicine is available in form for intravenous injection, however, in August 2020 Gilead intends to begin clinical trials more easy to use form LS – inhalation. The company explained that the delivery of the drug with a nebulizer will simplify its use in ambulatory patients.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]